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Alzheimer disease (AD) is a complex neurodegenerative 
disorder, whose prevalence will dramatically rise by 2050. 
Despite numerous clinical trials investigating this disease, 
there is still no effective treatment. Many trials showed 
negative or inconclusive results, possibly because they re-
cruited only patients with severe disease, who had not un-
dergone disease-modifying therapies in preclinical stages 
of AD before severe degeneration occurred. Detection of 
AD in asymptomatic at risk individuals (and a few presymp-
tomatic individuals who carry an autosomal dominant mo-
nogenic AD mutation) remains impractical in many of clini-
cal situations and is possible only with reliable biomarkers. 
In addition to early diagnosis of AD, biomarkers should 
serve for monitoring disease progression and response to 
therapy. To date, the most promising biomarkers are cer-
ebrospinal fluid (CSF) and neuroimaging biomarkers. Core 
CSF biomarkers (amyloid β1-42, total tau, and phosphorylat-
ed tau) showed a high diagnostic accuracy but were still 
unreliable for preclinical detection of AD. Hence, there is 
an urgent need for detection and validation of novel CSF 
biomarkers that would enable early diagnosis of AD in 
asymptomatic individuals. This article reviews recent re-
search advances on biomarkers for AD, focusing mainly on 
the CSF biomarkers. In addition to core CSF biomarkers, the 
potential usefulness of novel CSF biomarkers is discussed.
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According to the World Alzheimer Report, in 2009 35.6 mil-
lion people worldwide suffered from dementia. Alzheimer 
disease (AD) is the major primary cause of dementia and 
affects 60%-80% of demented people (1). Because of the 
longer life span and increasing number of elderly people, 
it is estimated that by 2050 this number will reach 115.4 
million (1). In absence of a cure for AD, current medications 
only alleviate the symptoms and have generally been test-
ed principally only in late-stage AD patients. The pathologi-
cal process in AD brain starts at least 10-20 years before the 
occurrence of the first dementia symptoms (2). Therefore, 
it is crucial to treat asymptomatic individuals, in whom de-
generation is not yet severe, with disease-modifying drugs 
(Figure 1) (3). Reliable biomarkers are essential as they are 
necessary for early AD detection at preclinical stages. Be-
sides an important role in diagnostics, biomarkers can also 
provide insight into the AD pathogenesis.
Biomarkers are usually analyzed in bodily fluids such as 
blood, urine, or the cerebrospinal fluid (CSF), but data col-
lected with brain imaging methods are also considered as 
biomarkers (4-6). To be accepted as such, a new marker of 
AD must fulfill two conditions: it must be evaluated in at 
least two independent peer-reviewed cross-sectional clini-
cal studies and be confirmed neuropathologically at autopsy 
(7). The key features of an ideal AD biomarker are sensitivity 
(probability of AD detection) and specificity (differentiation 
of AD patients from healthy individuals and patients with 
other primary causes of dementia) above 85%. Additional 
important characteristics are availability, non-invasiveness, 
reasonable cost, and potential for repeated measurements 
(Table 1) (7,8). A strong biomarker also should have high 
early diagnostic sensitivity and pathological specificity, and 
correlate with disease progression (Table 2). In general, bio-
markers are divided into two groups: biomarkers of exposure 
and biomarkers of disease. Biomarkers of exposure serve for 
the estimation of disease risk factors, while biomarkers of 
disease are used in screening (prognostic markers), diag-
nostic tests for early disease detection (diagnostic markers), 
and monitoring disease progression (staging markers). This 
group of biomarkers is also used in monitoring response to 
therapy (9,10). As such, reliable biomarkers are extremely 
important for the selection of patients for clinical trials, and 
consequently for treatment validation (11).
The existing diagnostic tests of AD are mostly based on 
neuropsychological assessment (12), which remains inad-
equate for early detection and differentiation of AD from 
other types of dementia, such as vascular dementia (VaD), 
frontotemporal dementia (FTD), or Lewy body disease 
FiGuRe 1. Longitudinal changes of Alzheimer disease biomarkers during the disease progression.
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(LBD). Probable AD is diagnosed after the onset of the first 
symptoms when degeneration is already substantial (13). 
Consequently, the European Federation of Neurological 
Societies recommended additional tests for AD diagnosis, 
including assessment of brain volumetry using magnetic 
resonance imaging (MRI) and measurement of tau protein 
in the CSF (14,15). Furthermore, Dubois et al (16) revised 
the generally accepted NINCDS-ADRDA (National Institute 
of Neurological and Communicative Disorders and Stroke 
and Alzheimer Disease and Related Disorders Association) 
criteria for AD diagnosis (17). In addition to the core diag-
nostic criteria, which mostly refer to monitoring of episodic 
memory impairment using a battery of neuropsychologi-
cal tests, supportive criteria should be considered, which 
include abnormal CSF biomarkers, medial temporal lobe 
atrophy, reduced glucose metabolism in the temporal and 
parietal regions, or the presence of an ε4 allele in the gene 
for apolipoprotein E (ApoE) (16). This refines the diagnosis 
by defining the stages of AD progression: at-risk state for 
AD (asymptomatic individuals with positive biomarkers), 
presymptomatic AD (autosomal-dominant mutation car-
riers), prodromal AD (mild episodic memory loss, positive 
biomarkers), and AD dementia (severe episodic memory 
loss, positive biomarkers) (Figure 1) (16). Through the initia-
tion and work of the Biomarker Consortium (18) and the Al-
zheimer Disease Neuroimaging Initiative (19), scientists and 
clinicians attempted to emphasize the importance of bio-
markers in early AD detection in asymptomatic individuals.
We reviewed the existing biomarkers of AD, with a special 
focus on the CSF. Also, alterations in novel CSF biomarkers, 
especially CSF neurotransmitters, during AD, their role in 
the disease process, and potential diagnostic applications 
are discussed.
CSF CoRe BioMARkeRS
Amyloid β protein
Senile plaques, one of the major neuropathological hall-
marks of AD, are formed as a result of excessive amyloid β 
(Aβ) protein production, aggregation, and deposition in 
the brain (20). In early-onset familial AD, these pathological 
processes are caused by mutations in the genes encoding 
proteins involved in the production of Aβ, whereas in spo-
radic AD an imbalance in formation and removal of Aβ is ob-
served. While in AD, pathological Aβ1-42 is formed after pro-
cessing of the amyloid precursor protein (APP) through the 
amyloidogenic pathway (β-secretase [BACE1] pathway), in 
healthy individuals prevails the non-amyloidogenic pathway 
(α-secretase pathway), in which Aβ1-42 is not formed (21).
Due to molecular exchange at the brain/CSF interface, 
pathological processes in the brain are frequently reflected 
in the CSF (22). Thus, numerous studies investigated the 
decrease in Aβ1-42 in the CSF of AD patients by enzyme-
linked immunosorbent assay (ELISA) (23-26). A 50% lower 
TABLe 1. Characteristics of Alzheimer disease (AD) biomarkers
Advantages Disadvantages
Cerebrospinal 
fluid biomarkers
High sensitivity and specificity; best reflection of 
pathological processes in the AD brain; diagnostic 
utility confirmed by many studies
Invasive sample collection by lumbar puncture; expensive 
ELISA tests; inter- and intra-laboratory variability; follow-up 
of the patients mostly not possible due to lumbar puncture
Neuroimaging 
biomarkers
High sensitivity and specificity; noninvasive; diagnostic 
utility confirmed by many studies
Sophisticated techniques; expensive radiotracers; not 
widely distributed
Plasma biomarkers Minimally invasive; possible follow-up of patients; 
screening of healthy population
Low sensitivity and specificity; conflicting results; still 
unavailable suitable plasma biomarkers
Genetic biomarkers Excellent for prediction of familial AD; noninvasive; 
low-cost genetic tests; screening of healthy population
No available genetic biomarkers for sporadic AD
TABLe 2. Diagnostic usefulness of established Alzheimer disease biomarkers
Biomarkers
Pathological 
specificity
early diagnostic 
sensitivity
Correlation with 
disease progression
Neuropsychological testing + ++ ++
Amyloid β1-42 ++ + +
t-tau ++ ++ +
p-tau +++ +++ ++
Magnetic resonance imaging + ++ +++
Positron emission tomography + ++ +++
*Minimum (+), moderate (++), maximum (+++).
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Aβ1-42 diffusion in the CSF can be explained by its deposi-
tion in senile plaques (27). However, because a reduction 
of CSF Aβ1-42 was noticed in other diseases like Creutzfeldt-
Jakob disease (CJD) and multiple system atrophy, in which 
senile plaques are not formed, it is believed that the re-
duction of Aβ1-42 levels in the CSF can be also mediated by 
other mechanisms (28,29). For instance, it can be a result of 
Aβ1-42 binding either to ApoE, cystatin C, or β-trace protein, 
accumulation in the form of oligomers, or sequestration in 
membranes (30).
CSF Aβ1-42 levels show high sensitivity (78%-100%) but in-
sufficient specificity (47%-81%) in differentiating AD pa-
tients from healthy controls (31). Although the accuracy of 
established cut-off levels is still discussed, levels of Aβ1-42 
lower than 500 pg/ml are generally considered compatible 
with AD (32). Levels of Aβ1-42 are not changed with aging 
and in pathological conditions like Parkinson disease, pro-
gressive supranuclear palsy, alcoholic dementia, depres-
sion, and stroke (29,33). However, Aβ1-42 decrease is also 
observed in LBD, FTD, VaD, amyotrophic lateral sclerosis, 
multiple system atrophy, CJD, and in neuroinflammation, 
resulting in insufficient Aβ1-42 specificity (28,29,33-35). Yet, 
Aβ1-42 reduction is observed very early, much before the 
occurrence of the first AD symptoms (36). Thus, measure-
ment of Aβ1-42 in CSF can facilitate the diagnostics of incipi-
ent AD in patients with mild cognitive impairment (MCI; 
MCI-AD) (37). Recent studies have assessed the diagnos-
tic usefulness of Aβ1-42, and showed that it is very unsta-
ble (degrading after 2 freeze-thaw cycles) and forms only 
10% of the total amyloid proteins in CSF. A more precise AD 
biomarker than Aβ1-42 alone is the Aβ1-42 /Aβ1-40 ratio, even 
though Aβ1-40 is slightly increased or unchanged in the CSF 
of AD patients (38).
Tau protein
Tau protein is the major component of neurofibrillary tan-
gles (NFT), the other key neuropathological hallmark of AD 
(39). It is located principally in the axons, connects micro-
tubules, and regulates axonal length, stability, and rigidity 
(40). Hyperphosphorylation of tau proteins leads to de-
tachment of tau from microtubules, degradation of micro-
tubules and consequently axons, and results in neuronal 
death (41). Abnormally phosphorylated tau proteins fur-
ther accumulate and form NFT (42-44).
Total tau in the CSF. Axon degradation and neuronal 
death lead to the release of tau proteins in the CSF. 
Many studies confirmed an increase in total tau (t-
tau) in the CSF of AD patients (25,26,45-47). Levels of t-
tau vary from 300 to 900 pg/ml and can be increased by 
as much as 300% in comparison to healthy controls (48). 
Because CSF t-tau levels increase with aging, cut-off val-
ues are adjusted by age. For patients 51-70 years old, lev-
els higher than 450 pg/ml are considered pathological, 
while above this age the cut-off value is 600 pg/ml (32). 
T-tau reached high sensitivity (84%) and specificity (91%) 
in differentiating AD patients from healthy individuals (48). 
These numbers should be taken with caution as elevation 
of CSF t-tau is also detected in VaD, FTD, CJD, stroke, and af-
ter traumatic brain injury (45-47,49-51). In all of these path-
ological conditions, t-tau is moderately elevated, except in 
CJD, where as a consequence of severe neuronal damage 
the levels of t-tau can reach 3000 pg/ml (52). Therefore, t-
tau is not a reliable biomarker for differentiation of AD from 
other types of dementia. Its levels are normal in the CSF 
of geriatric patients with major depression (MD). As early 
AD symptoms coincide with MD symptoms, measurement 
of CSF t-tau enables correct differentiation between these 
two groups and adequate treatment of patients with MD 
(53). Using t-tau as a biomarker, it is possible to detect in-
cipient AD in the group of MCI patients with high sensitiv-
ity and specificity (37). However, as in the case of Aβ1-42, it 
should be kept in mind that MCI can precede other types 
of dementia in which t-tau is also elevated (37).
Phosphorylated tau in the CSF. Out of the 85 (Dr Luc Buée, 
personal communication) possible phosphorylation sites 
(mainly on serines and threonines), tau protein is phos-
phorylated on approximately 71 sites in physiological or 
pathological conditions (54). Phosphorylation is regulated 
by numerous kinases, leading to different phosphorylation 
of tau at different stages of the disease (55). It has been re-
ported that in AD there is an increase in phosphorylated 
tau (p-tau) to approximately 250% of control levels (24,45-
48). Different p-tau epitopes have been measured in the 
CSF using ELISA method: threonine 231 (p-tau231), serine 
199 (p-tau199), threonine 181 (p-tau181), serine 235, and ser-
ine 369/404 (31,47,56-58). As p-tau reflects pathology in 
AD brain better than t-tau, very high specificity (92%) and 
sensitivity (80%) was reported in differentiating AD pa-
tients from healthy controls (31). Unlike t-tau, a general in-
dicator of degeneration and neuronal death, p-tau reflects 
the phosphorylation state of tau protein and the forma-
tion of NFTs in AD brain (59). However, it is still unknown 
what the main source of p-tau in the CSF is and whether 
neurons affected by tau pathology excrete p-tau in the ex-
traneuronal space and by which mechanism. These gaps in 
knowledge question the assumption that p-tau accurately 
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reflects NFTs in AD brain (60). Nevertheless, p-tau has more 
than 80% specificity in differentiating AD from other pri-
mary causes of dementia (61). Additionally, normal p-tau 
levels were found in pathological states like VaD, FTD, LBD, 
during depression, and after stroke, while fetal tau isoform 
is normally hyperphosphorylated during development 
(49,52,62,63). However, a moderate increase in p-tau was 
observed in CJD (52), as well as a decrease in both t-tau 
and p-tau in Parkinson disease (64). In a recent study, p-
tau has been used as a biomarker for detection of MCI-AD 
patients (38).
The most studied p-tau biomarkers are p-tau181, p-tau199, 
and p-tau231. In most clinical studies, t-tau, p-tau181, and 
Aβ1-42 are measured in the CSF as a part of routine analyses, 
with a cut-off level for p-tau181 being 60 pg/ml (32,56,57). 
p-tau181 was confirmed as a good biomarker in differenti-
ating AD from LBD and idiopathic normal pressure hydro-
cephalus (57,65). Additionally, Hansson et al (38) detected 
MCI-AD patients with 95% sensitivity and 83%-87% spec-
ificity by combining t-tau, Aβ1-42, and Aβ1-42/p-tau181 ratio. 
Regarding p-tau199 epitope, Itoh et al (66) detected AD us-
ing this biomarker with very high sensitivity and specificity 
(above 85%). Moreover, Boban et al (47) differentiated pa-
tients with FTD and AD with 88% accuracy by combining 
t-tau and p-tau199. However, p-tau181 and p-tau231 showed 
better results in early detection of AD (67). Elevation of p-
tau231 levels and correlation with cognitive decline was re-
ported in the group of MCI-AD patients (58,67). Addition-
ally, a multicenter study by Hampel et al (61) showed that 
CSF p-tau231was a stable biomarker of MCI conversion to 
AD. p-tau231 was also considered as a potential biomark-
er for differentiation of AD from VaD, LBD, and FTD (23). 
In conclusion, if CSF concentrations of all three p-tau bio-
markers are elevated, clinicians can be 90% confident that 
a patient is suffering from AD (68).
Longitudinal changes of CSF biomarkers
Most studies on CSF biomarkers have had cross-sectional 
rather than longitudinal design. However, data from lon-
gitudinal studies could be very useful in monitoring the 
response to therapy. Recent studies have shown CSF bio-
markers (Aβ1-42, t-tau, p-tau) to be stable from 6 months up 
to 2 years of disease progression and suitable for moni-
toring the CSF changes induced by therapy (69-71). On 
the other hand, Bouwman et al (72) reported an increase 
in Aβ1-42 and t-tau (but not p-tau) during AD progression, 
while two other studies indicated a decrease in Aβ1-42 in 
AD patients and in p-tau in the late stages of the disease 
(73,74). In addition, Toledo et al (75) described two distinct 
groups of participants with normal baseline CSF values: 
patients with stable and patients with abnormal longitu-
dinal CSF biomarkers (decreasing Aβ1-42 and increasing p-
tau181). They also reported that Aβ1-42 decrease precedes 
an increase in p-tau181, further supporting the notion that 
CSF Aβ1-42 changes appear before tau changes (75,76). The 
model of dynamic biomarkers proposed by Jack et al sheds 
light on these issues, confirming that CSF Aβ1-42 pathology 
precedes CSF tau pathology (Figure 1) (77,78). This model 
also suggests a sigmoid curve of abnormality of biomark-
ers during disease progression. According to this model, 
when dementia starts, most of the biomarkers have al-
ready reached the plateau phase (especially Aβ1-42) and 
do not change as much as in preclinical stages of disease 
(78). However, although Aβ1-42 CSF changes occur before 
tau changes, Braak et al confirmed the well-known find-
ing that tau aggregation preceded plaque formation in AD 
brain (60).
NoveL CSF BioMARkeRS
Besides core CSF biomarkers, other biomarkers could re-
flect AD pathological processes and improve the diagnos-
tics of AD (25). These novel biomarkers are mostly related 
to Aβ metabolism, degeneration, inflammation, or lipid 
metabolism. The most useful novel biomarkers related to 
Aβ metabolism are CSF BACE1 activity, levels of APP iso-
forms (sAPPα and sAPPβ), Aβ oligomers, and C-terminal 
truncated Aβ isoforms (Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-14, Aβ1-15, 
Aβ1-16) (79-83). In the CSF of AD patients there are also al-
tered levels of neprilysin and cystatin C proteins involved 
in Aβ metabolism (84,85). Also, an increase in CSF neuro-
modulin (GAP43), neurofilament proteins, and visinin-like 
protein 1 (VILIP-1) reflects degeneration that occurs in the 
AD brain (86,87). Other potential biomarkers of degen-
eration are α-dystroglycan, precursor of neural cell adhe-
sion molecule 1 (NCAM-120), neuronal pentraxin recep-
tor (NPR), cocaine- and amphetamine-regulated transcript 
(CART), glial cell-derived neurotrophic factor (GDNF), and 
brain-derived neurotrophic factor (BDNF) (88-90). Disease 
progression results in the alteration of many inflammatory 
factors in the CSF, like interleukin 1 (IL-1), IL-6, tumor necro-
sis factor alpha (TNF-α), transforming growth factor beta 
(TGF-β), S100 calcium-binding protein A7 (S100A7), com-
plement C1q, interferon–γ, and markers of microglial ac-
tivation: chemokine (C-C motif ) ligand 2 (CCL2), trigger-
ing receptor expressed on myeloid cells 2 (TREM2), and 
chitotriosidase (5,83,91-94). None of these proteins has 
been sufficient to make an AD diagnosis due to high 
CEREBROSPINAL FLUID PHYSIOLOGY AND MOVEMENT 352 Croat Med J. 2014;55:347-65
www.cmj.hr
variability among studies. However, chitinase-3-like pro-
tein 1 (YKL-40), a novel potential inflammatory biomarker, 
has been found to be elevated in very mild AD (94-96). In 
AD, there are also alterations in lipid metabolism. In spite of 
technically demanding detection approaches, biomarkers 
like F2-isoprostanes, 27-hydroxycholestrol (27OHC), ApoE, 
ApoJ, ApoA-I, and sphingolipids could serve as reliable bio-
markers of AD (97-100).
Simultaneous measurement of many AD biomarkers and 
the search for novel biomarkers could be facilitated by pro-
tein profiling of the CSF. Nowadays, this has been enabled 
by advanced proteomics techniques like 2D gel electro-
phoresis, protein microarrays, immunoprecipitation, vari-
ous types of mass spectrometry (surface-enhanced laser 
desorption/ionization-time of flight mass spectrometry 
[SELDI-TOF MS], matrix-assisted laser desorption/ioniza-
tion-time of flight mass spectrometry [MALDI-TOF MS], 
liquid chromatography-mass spectrometry [LC-MS]), and 
stable isotope labeling kinetics (SILK) (95,101-105). In fact, 
using 2D-DIGE (2D-difference gel electrophoresis) and LC-
MS/MS techniques, Perrin et al (96) detected 47 new po-
tential AD biomarkers in the CSF, 4 of which were addition-
ally confirmed by ELISA. Using LC-MS, Ringman et al (106) 
detected 56 proteins with altered expression in the CSF 
of AD patients (46 increased and 10 decreased). In addi-
tion, Simonsen et al (107) using MS detected a panel of 17 
proteins and peptides for differentiation between patients 
with stable MCI and MCI-AD.
CSF neurotransmitters in AD
Various studies have demonstrated the presence of per-
turbed neurotransmitter pathways in AD (108,109). As 
progressive failure of neuronal networks and neurotrans-
mitter systems is one of the prominent features of AD, it 
is not surprising that in the CSF of AD patients abnormal 
concentrations of neurotransmitters and their metabolites 
have been found. Hence, many studies tried to assess the 
diagnostic potential of CSF neurotransmitters (110,111). 
However, the results on CSF monoamine metabolites in 
AD patients are conflicting (112,113). Moreover, despite 
the decreased brain noradrenaline content and loss of no-
radrenergic neurons in the locus coeruleus detected in AD, 
CSF markers of noradrenergic metabolism have not been 
proven diagnostically useful (111,114). Conflicting results 
have also been obtained on CSF γ-aminobutyric acid 
(GABA), glutamate, and neuropeptides (110,115,116). 
Although previous studies demonstrated inconsistent 
findings, the implementation of new methods for 
determination of different neurotransmitters and their me-
tabolites in the CSF, such as LC-MS, showed some promis-
ing results (107,110,111). Namely, using this sensitive meth-
od, significant changes in the CSF levels of two important 
neurotransmitters/metabolites, adrenaline and 5-hydroxy-
indoleacetic acid (5-HIAA), which correlated with degener-
ation progression, were detected in a rat model for human 
tauopathy (117). Our study stressed the importance of ear-
ly noncognitive, behavioral, and psychological symptoms 
of dementia that are caused by perturbed function of the 
brainstem (118). More precisely, it is considered that many 
behavioral and psychological symptoms of dementia (con-
fusion, depression, agitation, disturbances in mood, appe-
tite, emotion, and wake-sleep cycle) are caused by early 
degeneration of serotonergic raphe nuclei (118).
As selective loss or impairment of cholinergic neurons 
represents an important aspect of AD, the CSF markers 
of cholinergic activity have been extensively investigated. 
Even though previous studies on CSF cholinergic markers 
obtained conflicting data (119,120), recent reports have 
demonstrated alterations in the molecular forms and gly-
cosylation patterns of acetylcholinesterase (AChE) in the 
CSF of AD patients, which reflect changes in the brain and 
might be useful as a marker of AD progression (121). It 
has been hypothesized that different AChE species and 
variants differ in their responses to disease and their in-
teractions with Aβ and abnormally hyperphosphorylated 
tau. Namely, accumulating evidence suggests that both 
Aβ and p-tau can trigger an AChE increase in the regions 
around amyloid plaques and NFTs, which can in turn in-
fluence presenilin 1 (PSEN1) and thereby modulate Aβ 
production (122). Moreover, according to some authors, 
low butyrylcholinesterase (BuChE) levels found in AD pa-
tient’s CSF are inversely related to BuChE in cortical amy-
loid plaques and could possibly predict extensive incor-
poration in neuritic plaques, increased neurotoxicity, and 
greater central degeneration (123). High ApoE and low 
BuChE levels in CSF strongly correlate with decreased ce-
rebral metabolic rate of glucose consumption (CMRglc), 
high cerebral Aβ load, and CSF p-tau of patients with prob-
able AD. These findings indicate that abnormally high lev-
els of ApoE might play a causative role in the pathological 
events of AD, particularly those involving the early cholin-
ergic deficit in the AD brain, through modulation of cho-
linesterases activities, hence disturbing the acetylcholine-
dependent activity of neurons and glial cells (124).
Because of the methodological limitations and differences 
between studies, CSF neurotransmitters did not have high 
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enough specificity and sensitivity to be considered as fa-
vorable biomarkers for AD. The observed discrepancy be-
tween the results obtained in various studies on CSF neu-
rotransmitters and their metabolites or enzymes involved in 
synthesis or degradation in AD could partially be explained 
by the impact of the post-mortem changes, the origin of 
the CSF samples (ventricular vs lumbar post-mortem CSF), 
or the different determination methods used. Although no 
individual CSF neurotransmitter changes were found to be 
specific for AD, it may be possible to develop a profile of 
several neurochemical parameters (111) with enhanced 
sensitivity and specificity, which could improve AD diag-
nosis with currently established biomarkers. Broader bio-
marker investigations should lead to a better understand-
ing of early disease mechanisms and the diagnosis of AD in 
the preclinical stages (125,126). Additionally, it should not 
be ignored that distribution of various substances along 
the CSF spaces depends on the rate of their removal into 
microvessels: faster removal means more limited distribu-
tion (127). Several studies demonstrated that organic ac-
ids pass freely between central nervous system (CNS) and 
CSF and vice versa and that active transport across capil-
lary walls acts as a “sink” in their elimination from CNS and 
CSF. Thus, organic acids (for example 5-HIAA) pass from cis-
ternal CSF into the CNS parenchyma, where they are being 
eliminated into capillaries by means of a powerful active 
transport, resulting in a swift decrease of their concentra-
tion inside the cisternal CSF, so they cannot be significantly 
distributed to remote CSF compartments (lumbar suba-
rachnoid space) (128-131). This observation suggests that 
lumbar CSF concentration of neurotransmitter’s metabo-
lites better reflects local changes inside the spinal cord tis-
sue than metabolic activity of upper CNS compartments.
oTHeR BioMARkeRS oF AD
Neuroimaging biomarkers
In addition to CSF biomarkers, the most promising bio-
markers of AD proved to be neuroimaging biomarkers 
(14,132). Magnetic resonance imaging (MRI) is a structural 
imaging technique that reveals abnormalities in the brain 
structure in high resolution. The earliest change in AD 
brain that can be detected using MRI is atrophy of the hip-
pocampus and entorhinal cortex. But since these changes 
have also been detected in FTD and VaD, only MRI is not 
sufficient for the diagnosis of AD (133-135). Functional MRI 
(fMRI) used for the measuring alterations in the brain blood 
flow occurring due to neuronal activity has been recently 
considered as a method in diagnostics of dementia. AD pa-
tients had decreased neuronal activity in the hippocampus 
and parietal lobe, while neuronal activity in the primary (id-
iotypic) cortex, unaffected in AD, was increased (136). Al-
though fMRI detected alterations in functional connectiv-
ity of the fusiform gyrus to the areas within the ventral and 
dorsal visual pathways in MCI patients, this method is still 
not applicable in diagnostics of dementia due to high in-
ter- and intra-individual variability (137). Our recent study 
(138) has stressed the importance of fMRI in default mode 
network (DMN) imaging as a possible early new biomarker 
of AD. DMN, a major resting-state network in our brain is 
innervated by long projection fibers of noradrenergic, se-
rotonergic, and cholinergic neurons from the brain stem 
that can release high amounts of Aβ in DMN hub regions. 
Additionally, due to their constant activity, neurons from 
DMN regions produce and release more Aβ than they do 
elsewhere in the cortex. This Aβ overload can lead to a 
functional impairment of DMN, which can be detected by 
fMRI very early, before the first dementia symptoms occur 
(138).
Of all neuroimaging techniques, the most promising is 
positron emission tomography (PET), which measures al-
terations in brain metabolism. Using this technique hypo-
metabolism was reported, namely reduced cortical FDG 
(18F-fluorodeoxyglucose) uptake in the parietal, temporal, 
and posterior cingulate cortex of AD patients (139). Also, 
this method reached specificity and sensitivity of 93% 
and 84%, respectively, in differentiating AD from healthy 
control patients (140). Using other PET radiotracers – PiB 
(Pittsburgh Compound-B) and [18F]FDDNP (2-(1-{6-[(2-[18F]
fluoroethyl)(methyl) amino]-2-naphthyl}ethylidene)ma-
lononitrile), this method can detect either senile plaques 
alone or both NFTs and senile plaques, respectively (141-
144). Leuzy et al (145) stressed the possibility of amy-
loid PET imaging usage in personalized medicine. When 
combined with MRI, amyloid imaging showed very high 
specificity and sensitivity in early detection of AD. Also 
in addition to PiB and [18F]FDDNP, two more radiotracers 
have been approved for amyloid imaging: [18F]florbetapir 
(Amyvid) and [18F]flutemetamol (Vizamyl), plus other two 
still in phase III of clinical trials: [18F]-labeled florbetaben 
and [18F]-NAV4694 (138,145). Tau deposits have been visu-
alized by [18F]-labeled T808 and [11C]-labeled phenyl/pyrid-
inyl-butadienyl-benzothiazoles/benzothiazolium [PBB3] li-
gands that also reached phase III of clinical trials (138). The 
clinical application of selective tau imaging biomarkers is 
expected to become more and more important as it pro-
vides important information regarding tau pathophys-
iology in AD and non-AD tauopathies, allowing 
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correlation of brain tau load with cognitive function, moni-
toring disease progression and evaluation of therapeutic 
efficacy of newly developed drugs aimed at modulating 
tau pathology (146).
Although neuroimaging methods reported excellent re-
sults in early detection and differentiation of AD, they are 
unfortunately still unavailable as a diagnostic tool in many 
clinical centers and hospitals due to the high costs of the 
technology itself and of the radiotracers. A significantly 
cheaper, but useful neuroimaging method – SPECT (single 
photon emission computerized tomography), commonly 
used for blood flow measurement, reliably revealed hypo-
metabolism of the temporo-parietal and prefrontal corti-
ces in AD patients in comparison to healthy elderly con-
trols (147). Unfortunately, in spite of its wide availability, 
SPECT is still underused in the assessment of AD and re-
lated dementias.
Plasma biomarkers
Numerous studies searched for reliable AD biomarkers in 
blood (plasma rather than serum), because lumbar punc-
ture is still considered a relatively invasive method. Un-
fortunately, none of the potential plasma biomarkers is 
prognostically or diagnostically adequate due to their bio-
availability. Those biomarkers that finally enter the plasma 
are highly diluted and adhere to various proteins (148). 
Aβ is the most studied plasma biomarker of AD. However, 
different studies yielded conflicting results, to the extent 
that some studies observed an increase in plasma Aβ1-42 
and Aβ1-40, increase in Aβ1-42 (but not Aβ1-40), increase in 
Aβ1-40 (but not Aβ1-42), or unaltered levels of both proteins 
(148,149). Decreased Aβ1-42 /Aβ1-40 ratio was also reported 
as a risk factor for MCI conversion to AD (150). In fact it re-
mains unclear whether plasma Aβ truly reflects the situa-
tion in the brain because Aβ is also produced elsewhere in 
the body (151).
Plasma levels of α2-macroglobulin, complement factor H, 
homocysteine, cholesterol, F2-isoprostanes, Aβ autoan-
tibodies, and ApoA1 have also been measured (148,152-
155). None of these potential biomarkers reached satisfy-
ing sensitivity and specificity. However, Manzine et al (156) 
observed reduced expression of platelet ADAM10 (A Dis-
integrin And Metalloproteinase), stressing the possibility 
of its use as an early biomarker of AD. It is believed that 
a combination of plasma biomarkers could result in di-
agnostically useful screening tests. Thus, only patients 
with suspected dementia would be subjected to de-
termination of highly specific and sensitive neuroimaging 
and CSF biomarkers (157).
Genetic biomarkers
Familial AD (prevalence around 0.1%) is related to mutations 
in the genes for APP, PSEN1, and presenilin 2 (PSEN2) (158). 
However, the genetic causes of sporadic AD are not yet un-
derstood (159). The only well-known risk factor for AD is the 
ε4 allele of APOE gene. One ε4 allele triples the risk of AD, 
while two ε4 alleles increase the risk 15 times (160). Using 
genome-wide association studies (GWAS), scientists have at-
tempted to detect new gene variants involved in the emer-
gence of sporadic AD (161,162). In fact, a recent study de-
tected 120 gene loci associated with AD (163). Cruchaga et 
al (164) reported that the presence of a rare variant Val232-
Met in PLD3 (phospholipase D3) doubles the risk for sporad-
ic AD. As PLD3 influences APP processing, any impairment 
of PLD3 function leads to the aberrant APP processing.
The other approach is comparison of gene expression be-
tween AD patients and healthy controls. Gene expression 
profiling can be done by using the RNA extracted from the 
cells precipitated in the pellets of CSF samples or periph-
eral blood. As a large number of studies reported altered 
gene expression in AD, this approach is also considered for 
AD diagnosis (165,166).
CoMBiNATioN oF BioMARkeRS
While measurement of single biomarkers (especially p-
tau) resulted in very high sensitivity and specificity, com-
bining more CSF biomarkers can improve diagnostic ac-
curacy (Table 3) (8,23,38,95,141,167-173). Shaw et al (171) 
combined Aβ1-42, t-tau, and p-tau181 with the purpose of es-
tablishing a “signature of AD,” resulting in mixed data. The 
Luminex xMAP technology (Luminex, Austin, TX, USA) used 
in the measurement of Aβ1-42, t-tau, and p-tau181 in increas-
ingly more studies proved as accurate as standard ELISA 
methods. The additional and preferable characteristic of 
this technology is that it measures all CSF biomarkers in 
the same CSF aliquot (174). Spies et al (175) developed a 
very accurate prediction model for determination of AD 
probability among individuals suspected of dementia. This 
model, based on logistic regression analysis, calculates the 
probability of AD from the levels of CSF biomarkers (Aβ1-42 
and p-tau181) and the patients’ gender. Variability in the val-
ues of CSF biomarkers due to differences in pre-analytical 
and analytical procedures or differences in ELISA kits from 
various manufacturers still represents a major problem. 
355Babić et al: CSF core and developing biomarkers in diagnosis of AD
www.cmj.hr
TABLe 3. Characteristics of biomarker combinations used for diagnosing Alzheimer disease
Combination of biomarkers observations References
CSF Aβ1-42
t-tau
Sensitivity 85%-94%, specificity 83%-100% in differentiating AD from HC  (8)
t-tau/Aβ1-42 ratio 1. Sensitivity 89% in detection of MCI-AD patients
2. More accurate prediction of conversion from normal or MCI to AD
1 (171).
2 (95,141,169).
p-tau181/Aβ1-42 1. Differentiation of AD from HC – sensitivity 86%, specificity 97%; Differentiation 
of AD from other dementias – sensitivity 80%, specificity 73%
2. Better prediction of MCI conversion to AD
1 (168).
2 (141).
Aβ1-42
t-tau
p-tau181
1. Sensitivity 95%, specificity 83% in detection of MCI-AD patients
2. Sensitivity 83%, specificity 72% for differentiation of MCI-AD patients from 
stable MCI
3. Luminex xMAP technology for simultaneous measurement of all 3 core CSF 
biomarkers
1 (38).
2 (170).
3 (174,184).
p-tau181
Aβ1-42/Aβ1-38 ratio
Sensitivity 94%, 85% specificity in differentiating AD from other primary causes 
of dementia
 (172)
Aβ1-42, t-tau
F2-isoprostanes
Sensitivity 84%, specificity of 89% in differentiating AD from HC and other 
dementias
 (167)
CSF + 
neuroimaging
Aβ1-42
PiB-PET
Decreased CSF Aβ1-42 and increased PiB binding in the brain of AD patients  (27,142,185)
t-tau/Aβ1-42, p-tau/Aβ1-42
PiB-PET
Better correlation of these ratios than Aβ1-42 alone with PiB binding in the 
brain of AD patients
 (143,186)
Aβ1-42
t-tau, p-tau181
MRI
Association of:
1. WBA with decrease of Aβ1-42 in preclinical AD plus correlation of t-tau and 
p-tau181 with further atrophy caused by disease progression
2. Hippocampal volume with CSF t-tau and p-tau
1 (24)
2 (187)
t-tau/p-tau181
Aβ1-42
MRI
Results of longitudinal study indicated that higher normal WBA slows the 
occurrence of dementia symptoms in individuals with pathological values of 
CSF biomarkers
 (188)
t-tau/p-tau181
Aβ1-42
rCBF
MCI patients with reduced regional cerebral blood flow in the parietal cortex 
and pathological levels of CSF biomarkers had higher risk of AD
 (189)
t-tau, p-tau231
isoprostanes
Aβ1-42/Aβ1-40
MRI
More accurate detection of MCI-AD patients by combination of CSF biomarkers 
and measurement of medial temporal lobe atrophy using MRI. 74%-84% 
accuracy of MCI-AD detection after combination of p-tau231 and MRI.
 (190)
VILIP-1
t-tau, p-tau181
Aβ1-42
MRI, PiB-PET
CSF VILIP-1 positively correlated with tau, p-tau181 and PiB binding and 
negatively with WBA. VILIP-1/Aβ1-42 predicted cognitive impairment as well as 
p-tau181/Aβ1-42 and tau/Aβ1-42
 (173)
CSF + 
neuroimaging + 
genetic 
testing
Aβ1-42
PIB-PET
APOE genotype
APOE ε4 allele carriers had elevated PiB binding in the brain and decreased CSF 
Aβ1-42, while APOE ε2 allele had protective effect
 (191)
PIB-PET
APOE genotype
Increased PiB binding in the brain of APOE ε4 allele carriers  (192,193)
BACE1 activity
APOE genotype
Increased BACE1 activity at APOE ε4 allele carriers  (194)
Aβ1-42, p-tau181,
BIN1, CLU, CR1, PICALM 
genotype
Variants of BIN1, CLU, CR1 and PICALM genes associated with susceptibility 
for AD do not affect CSF Aβ1-42 and p-tau181
 (195)
p-tau181, PPP3R1 geno-
type
Rs1868402 variant of PPP3R1 gene associated with higher levels of p-tau181 and 
faster progression of AD
 (196)
*Abbreviations: CSF – cerebrospinal fluid; Aβ – amyloid β; AD – Alzheimer disease; HC – healthy controls; MCi – mild cognitive impairment; PiB – 
Pittsburgh Compound-B; WBA – whole brain atrophy.
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While analytical factors refer to laboratory procedures in 
different laboratories (176), pre-analytical variability is re-
lated to the selection of participants and treatment of CSF 
samples after lumbar puncture (eg, the tube type, storage 
temperature, and the number of freeze/thaw cycles before 
analysis) (50,177,178). It is difficult to influence the vari-
ability caused by differences among ELISA kits of various 
manufacturers (179). Our recent study indicates that there 
are differences between t-tau and Aβ1-42 ELISA kits from 
different vendors, making it impossible to use them inter-
changeably (26). Fagan et al (143) also reported differences 
in the absolute values of CSF Aβ1-42, t-tau, and p-tau181 after 
measurement by the two most frequently used methods 
(INNOTEST ELISA and INNO-BIA AlzBio3 assay on Luminex 
xMAP technology [Luminex]). The Alzheimer Association in 
2009 initiated an international quality control program for 
CSF biomarkers. The results for 2010-2012 showed that co-
efficients of variation among laboratories are still very high, 
ranging from 20% to 30% (180). Thus, the debate is still on 
if the established cut-off levels for Aβ1-42, t-tau, and p-tau181 
should be widely used (32) or every laboratory should de-
fine internally qualified cut-off levels (180).
Detection of AD in asymptomatic individuals is still very 
difficult, even in specialized centers. With the emergence 
of new drugs for AD, it is likely that the diagnosis will be 
based on combinations of different biomarkers (36). 
Dubois et al (16) suggested that for diagnosing AD, APOE 
genotype and neuroimaging biomarkers should be deter-
mined besides CSF biomarkers. Therefore, recent efforts on 
AD biomarkers have focused on improving AD diagnosis 
by a combination of different biomarkers (CSF, neuroimag-
ing, and genetic biomarkers) (Table 3).
A recent MEDLINE search for the most common biomark-
ers of AD (Aβ, tau, MRI, PIB-PET, FDG-PET) performed by 
Noel-Storr et al (181) resulted in 19 104 published referenc-
es, 1032 of which were cross-sectional studies, 500 longitu-
dinal studies, while the rest of the publications was not rel-
evant. Because of the number of studies performed on AD 
biomarkers, scientists also use meta-analysis as a tool for 
the assessment of biomarker variability or validity and to 
stress the need for methodology standardization among 
investigations, with an ultimate goal to facilitate the diffi-
cult process of biomarker validation (37,181,182).
CoNCLuSioNS
Determination of different biomarkers for AD is expen-
sive and unfortunately still untenable in many institu-
tions. Due to a non-invasive method of sample collection, 
the best choice are considered to be biomarkers measured 
in blood (plasma or serum) or urine. Unfortunately, these 
biomarkers showed little accuracy in diagnostics of AD 
(183). The second choice are CSF biomarkers because lum-
bar puncture is still considered as an invasive procedure. 
Neuroimaging biomarkers are the last choice due to the us-
age of expensive radiotracers and sophisticated techniques 
that are still not widely available. For comparison, MRI and 
PIB-PET are 3 to 25 times more expensive, respectively, than 
measurements of Aβ1-42, t-tau, and p-tau181 concentration in 
the CSF (Table 1). However, the diagnostic potential of these 
well-established core CSF biomarkers should be further im-
proved by novel CSF biomarkers, warranting further studies 
on their detection and evaluation. This should decrease the 
age limit of AD detection, enable disease detection in pre-
clinical stage (Figure 1), and consequently facilitate the ad-
ministration of potential therapeutics to AD patients before 
irreversible degeneration occurs.
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